UNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research[1].
UNC7467 (2.5 μM; 3 hours; HCT116 cells) reduces levels of inositol pyrophosphates. UNC7467 reduces 5-InsP7 levels by 81% and 5-InsP8 levels by 63%[1].
UNC7467 (5 mg/kg; i.p.; daily, for 4 weeks; diet-induced obesity mice) ameliorated diet induced obesity, insulin resistance, and hepatic steatosis[1].
UNC7467 (1-5 mg/kg; i.v. and i.p.; diet-induced obesity mice) exhibits low clearance (13.7 (mL/min)/kg) and large AUClast (6054 h•ng/mL for intra venous (i.v.) and 2527 h•ng/mL for intraperitoneal (i.p.)) in mice at 5 mg/kg dose[1].
| Animal Model: | Diet-induced obesity (DIO) mice[1] |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; daily, for 4 weeks |
| Result: | Improved glycemic profiles, ameliorated hepatic steatosis, and reduced weight gain without altering food intake. |
| Animal Model: | Diet-induced obesity (DIO) mice[1] | ||||||||||||
| Dosage: | 5 mg/kg (Pharmacokinetic Analysis) | ||||||||||||
| Administration: | Intravenous injection and intraperitoneal injection | ||||||||||||
| Result: |
|
[1]. Zhou Y, et, al. Development of Novel IP6K Inhibitors for the Treatment of Obesity and Obesity-Induced Metabolic Dysfunctions. J Med Chem. 2022 May 12;65(9):6869-6887.